Regenxbio Inc To Discuss Interim Clinical Data Transcript
(Operator Instructions)
With that, I will now turn the call over to Ken Mills, CEO of REGENXBIO.
Good morning, everyone and thanks for joining us today. Today, we're excited to share new positive efficacy data from the AFFINITY DUCHENNE trial of RGX-202 for the treatment of Duchenne. Since our last update on February 7, we continue to be very encouraged by the data we have observed in this trial. (Event Instructions) Turning to the second slide of this presentation, you will see that today's event will include forward-looking statements and here is our forward-looking statement's disclosure. Please be advised that today's call is being recorded and webcast.
Okay. Let's move to slide 3 and here's our agenda. I will give an overview of today's positive updates. Then Dr. Steve Pakola, our Chief Medical Officer, will review the data from the AFFINITY DUCHENNE trial. Importantly, we're pleased to have Dr. Aravindhan Veerapandiyan, principle trial investigator on today's call and to engage in a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
